<?xml version='1.0' encoding='utf-8'?>
<document id="19346040"><sentence text="Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus."><entity charOffset="89-99" id="DDI-PubMed.19346040.s1.e0" text="tacrolimus" /></sentence><sentence text="Concomitant use of immunosuppressive agents and antiretroviral drugs may lead to complex drug-drug interactions" /><sentence text=" The calcineurin inhibitor tacrolimus is metabolized by cytochrome P-450 3A4 (encoded by the CYP3A4 gene) and is a substrate of P-glycoprotein (encoded by the ABCB1 gene)"><entity charOffset="27-37" id="DDI-PubMed.19346040.s3.e0" text="tacrolimus" /></sentence><sentence text=" Both pathways can be inhibited by protease inhibitors (PIs)" /><sentence text=" The reduction in first-pass and postabsorptive metabolism of tacrolimus by PIs can lead to extreme prolongation of the elimination half-life and significantly increase tacrolimus trough levels"><entity charOffset="62-72" id="DDI-PubMed.19346040.s5.e0" text="tacrolimus" /></sentence><sentence text=" In a patient with human immunodeficiency virus (HIV)-associated focal segmental glomerulosclerosis leading to kidney cadaveric transplantation, HIV salvage therapy was started with the new PI darunavir and boosted with ritonavir, another PI"><entity charOffset="193-202" id="DDI-PubMed.19346040.s6.e0" text="darunavir" /><entity charOffset="220-229" id="DDI-PubMed.19346040.s6.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.19346040.s6.e0" e2="DDI-PubMed.19346040.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19346040.s6.e0" e2="DDI-PubMed.19346040.s6.e1" /></sentence><sentence text=" The reduction in first-pass and postabsorptive metabolism of tacrolimus by PIs led to a dramatic increase in tacrolimus trough levels and extreme prolongation of the elimination half-life"><entity charOffset="62-72" id="DDI-PubMed.19346040.s7.e0" text="tacrolimus" /></sentence><sentence text=" Trough levels of tacrolimus levels were as high as 106"><entity charOffset="18-28" id="DDI-PubMed.19346040.s8.e0" text="tacrolimus" /></sentence><sentence text="7 ng/mL" /><sentence text=" A decrease in tacrolimus dosage to a single dose of 0" /><sentence text="5 mg/wk, corresponding to 3" /><sentence text="5% of the usual dose, enabled maintenance of stable tacrolimus trough levels"><entity charOffset="52-62" id="DDI-PubMed.19346040.s12.e0" text="tacrolimus" /></sentence><sentence text=" Our case highlights that coadministration of a PI and tacrolimus is feasible through intense reduction in dose and prolongation of the dosing interval of the calcineurin inhibitor"><entity charOffset="55-65" id="DDI-PubMed.19346040.s13.e0" text="tacrolimus" /></sentence><sentence text=" Complex drug interactions may become more frequent because more HIV-infected patients are undergoing transplantation and newer HIV drugs are being used" /><sentence text=" Close monitoring and excellent adherence are mandatory to avoid the risk of harm for the graft and patient" /><sentence text="" /></document>